Syndicated Content about Biotechnology, Pharmaceutical and Healthcare

05:26 EDT 29th July 2015 | BioPortfolio

Latest global life science, pharmaceutical and healthcare news syndicated from over 50 publishers. 

Showing News Articles 1–25 of 230,000+

Wednesday 29th July 2015

Merck acquires immune-oncology specialist cCAM

Merck acquires immune-oncology specialist cCAM

2nd-qtr sales of Gilead Sciences new hepatitis C shine, beating expectation

USA-based Gilead Sciences surprised investors when it reported second-quarter 2015 financials late Tuesday…

NICE draft guidance restricts use of Daklinza for hepatitis C

The National Institute for Health and Care Excellence (NICE), the medicines cost:benefit watchdog for…

ImmuPharma's chairman passes away

There has been some sad news from ImmuPharma (LON:IMM), which revealed that company chairman Richard Warr died last week. "No words can truly convey the deep sadness we feel at Richard's untimely passing away,” said Dimitri Dimitrou, chief execut...

RPT-UPDATE 1-Indonesian airline Garuda swings to profit in H1, shares jump

JAKARTA, July 29 (Reuters) - Indonesian flagship airline PT Garuda Indonesia Tbk swung to a net profit in the first half of 2015 from a loss a year earlier, sending its shares up more than 7 percent on Wednesday.

Deltex Medical expects early revenues from US approval of children's product

Deltex Medical (LON:DEMG)  has been given approval to sell its paediatric blood flow monitoring probes in the US by the Food and Drug Adminstration. The probe is designed to be used alongside Deltex’s CardioQ-ODM+ monitors on children who we...

BRIEF-Zealand Pharma: Sanofi announces first LixiLan Phase III trial's primary study endpoint

* Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint

UPDATE 1-Bayer profit boosted by new drugs, better plastics margins

* Cuts 2015 sales outlook to account for diabetes care unit sale

BRIEF-Diamyd Medical: new patent issued

* University of California has been granted key patent for combo treatment for type 1 diabetes with GABA and preproinsulin or an immunogenic fragment thereof

Zealand Pharma A/S: CORRECTION: Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint

Copenhagen, 2015-07-29 08:28 CEST (GLOBE NEWSWIRE) -- -- The LixiLan GLP-1/basal insulin combination showed statistically superior lowering of average blood glucose (HbA1c) compared with lixisenati...

BRIEF-Doxa Q2 net loss narrows to SEK 3.7 million

* Q2 revenue 4.3 million Swedish crowns ($501,000) versus 2.1 million crowns year ago

BRIEF-Skandion Clinic reconfirms C-RAD procurement

* The Skandion Clinic (Skandionkliniken) in Uppsala, Sweden has reconfirmed its previous decision to equip its proton therapy center with the C-RAD surface tracking solution Source text for Eikon:

Frisches Geld für Boehringer: Boehringer verkauft sein US-Generika-Geschäft. Der Käufer ist der britische ...

Boehringer verkauft sein US-Generika-Geschäft. Der Käufer ist der britische Konkurrent Hikma. Das Geld kann der rheinland-pfälzische Pharmakonzern gut gebrauchen - ungeplante Ausgasben hatten zulet...

Swiss stocks - Factors to watch on July 29

ZURICH, July 29 (Reuters) - The Swiss blue-chip SMI was seen opening up 0.25 percent at 9298.5 points on Wednesday, according to premarket indications by bank Julius Baer .

Novo Nordisk: Wachstumsaktie im Diabetis-Markt!

Die Aktie des Protein-Spezialisten Novo Nordisk aus Dänemark hat sich aus einem Seitwärtstrend, den man seit März beobachten konnte, seit Anfang Juli befreit und musste dann wieder einige Punkte ab...

NIH sets sights on $323m more for Alzheimer's

The NIH announced in April it planned to submit such a request – something Congress actually required the agency to do under the fiscal year 2015 federal appropriations legislation enacted in December 2014.

Zealand Pharma A/S: Sanofi has announced that the first LixiLan Phase III trial, LixiLan-O, met primary study endpoint

Copenhagen, 2015-07-29 07:56 CEST (GLOBE NEWSWIRE) -- -- The LixiLan GLP-1/basal insulin combination showed statistically superior lowering of average blood glucose (HbA1c) compared with lixisenati...

Eli Lilly Raises Hope of Alzheimer’s Breakthrough

A new experimental Alzheimer’s drug, solanezumab, developed by Eli Lilly has raised hopes for a breakthrough in the treatment of the disease. The progress was reported at the Alzheimer’s Association International Conference in Washington ...

BRIEF-Txcell appoints Masthercell for the manufacturing of Ovasave

* Appoints Masthercell for the manufacturing of lead product Ovasave Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Bayer adj EBITDA jumps 33 pct on higher drug sales, forex gains

FRANKFURT, July 29 (Reuters) - German drugmaker Bayer saw underlying core earnings increase by one third in the second quarter, helped by strong overseas currencies and a gain in prescriptions of new drugs such a stroke prevention pill Xarelto.

Novartis veräussert klinische Assets an Mereo BioPharma im Austausch für Aktien

Zürich (awp) - Der Pharmakonzern Novartis gliedert drei klinische Vermögenswerte im mittleren Stadium aus und veräussert diese an die Mereo BioPharma Group. Novartis erhalte im Gegenzug Aktien des ...

Novartis Reports Swap Of Clinical Assets For Equity With Mereo BioPharma

BASEL (dpa-AFX) - Swiss drugmaker Novartis (NVS) Wednesday announced a swap of clinical assets for equity with Mereo BioPharma Group Ltd. The deal involves compounds in areas of unmet medical need...

Ibrance, Prevnar 2Q sales validate Pfizer's R&D investments

Pfizer's investments in research and development paid off during the second quarter when the company generated $11.9bn in revenue, including better than expected sales for the new breast cancer drug Ibrance (palbociclib) and the pneumococcal vaccine....

Gerresheimer zieht an GFT und Nordex vorbei

Gewinne laufen lassen, Verluste begrenzen - lautet eine bekannte Börsenweissheit. Klingt zunächst einfach und recht logisch, in der Praxis sieht die Sache aber vielfach anders aus. Denn es gilt zw...

BRIEF-4SC gets EUR 29 mln from capital increase

* Gross issue proceeds 29 million euros ($32.06 million), representing upper end of targeted volume range Source text for Eikon: Further company coverage: ($1 = 0.9045 euros) (Gdynia Newsroom)



Advertisement
 
Advertisement